Euclid claims the drug delivery system improves glaucoma patient compliance by providing sustained release of active ingredients over a period of months.
Ora operates both clinical research facility and a primary care ophthalmic practice as well as a large international investigator site network called OraNET.
Euclid Systems president and CEO Bruce DeWoolfson said Ora’s specific experience with the clinical and regulatory aspects of ophthalmic drug delivery systems makes them the ideal partner for their technology, and they look forward to collaborate with the Ora team on bringing this technology into clinical development.
Ora president and CEO Stuart Abelson said they are excited to work with Euclid on developing their drug delivery platform, and they believe that its launch improves glaucoma patient compliance and validate the technology for additional indications, such as retinal disease.
